Gemtuzumab ozogamicin is a monoclonal antibody drug for the treatment of acute myeloid leukemia (AML). This drug uses a different strategy to classical chemotherapeutic agents, and the development of other similar drugs is expected to drastically improve the outcomes of patients with AML. In this interview, Chrisoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, also discusses treatments that have recently received FDA approval, such as CPX-351, a liposomal formulation of cytarabine and daunorubicin that has been approved for the treatment of secondary AML in the US, and isocitrate dehydrogenase (IDH) inhibitors. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Immunotherapies for the treatment of AML
